Economic burden and costs of chronic migraine

Current Pain and Headache Reports

Volumn 18, Issue 1, 2014, Pages

  Lanteri Minet, Michel ^a  

^a University of Côte d'Azur   (France)

Author keywords

Burden; Chronic migraine; Cost effectiveness; Direct costs; Epidemiology; Episodic migraine; Healthresourceuse; Indirect costs; Lost productivity time; MIDAS

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ABSENTEEISM; CHRONIC DAILY HEADACHE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG ABUSE; DRUG CHOICE; DRUG EFFICACY; EPISODIC MIGRAINE; GENERAL PRACTITIONER; HEADACHE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HOSPITAL SERVICE; HOSPITALIZATION; HUMAN; LICENCE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NERVE STIMULATION; NEUROLOGIST; PREVALENCE; PRODUCTIVITY; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; TRANSFORMED MIGRAINE; TREATMENT DURATION; CHRONIC DISEASE; DISABLED PERSON; ECONOMICS; FEMALE; HEALTH SURVEY; MALE; MIGRAINE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ABSENTEEISM; CHRONIC DISEASE; COST OF ILLNESS; DISABILITY EVALUATION; DISABLED PERSONS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIGRAINE DISORDERS; PREVALENCE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84889873210     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-013-0385-0     Document Type: Review

References (27)

1. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-6. (Pubitemid 17152607)
2. Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near daily headache. Proposed revisions to the IHS criteria. Headache. 1994;34:1-7. (Pubitemid 24038967)
3. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised criteria. Neurology. 1996;47:871-5.
4. Headache Classification Committee; Olesen J, Bousser MG, Diener HC, et al. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24(suppl 1):9-160.
5. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:1409-10.
6. •• Headache Classification Committee. The International Classification of Headache Disorders: 3rd edition beta version). Cephalalgia 2013;33:629-808. International Headache Society published in July 2013 the third edition of the International Classification of Headache Disorders (ICHD-3) with revised diagnostic criteria for chronic migraine. Clinicians and researchers should start using ICHD-3 criteria.
7. Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013;53:230-46.
8. Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599-609.
9. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15:70-8.
10. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86-92.
11. • Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine - classification, characteristics and treatment. Lancet Neurol. 2012;28:162-71. Diener and colleagues provide an excellent review on the evolution of our understanding of chronic migraine with focus on epidemiology pathophysiology, clinical features and treatment options.
12. Aurora SK, Dodick DW, Turkel CC, DeGryse R, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793-803.
13. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse R, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-14.
14. Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, et al. Cephalalgia. 2012;32:1165-79.
15. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuses: a systematic review. Cephalalgia. 2011;31:837-50.
16. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49:495-508.
17. Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, et al. The International Burden of Migraine Study (IBMS): study design, methodology and baseline cohort characteristics. Cephalalgia. 2011;31:1116-30.
18. •• Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301-15. This article provides global results of IBMS in terms of healthcare resource use and lost productivity time related to chronic migraine.
19. •• Stokes MS, Werner JB, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al. Cost of health care among patients with chronic migraine and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS). Headache. 2011;51:1058-77. This article provides detailed results of IBMS for North America (USA and Canada) in terms of costs of healthcare resource use related to chronic migraine.
20. •• Bloudek LM, Stokes M, Buse DC, Wilcox TTK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results of the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361-78. This article provides detailed results of IBMS for Western Europe (France, Germany, Italy, Spain UK) in terms of costs of healthcare resource use related to chronic migraine.
21. •• Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33:171-81. This clinic-based survey performed in Taiwan is the first to give detailed results about healthcare resource use and lost productivity time in Asia/Pacific region.
22. Buse DC, Lipton RB. Global perspectives on the burden of episodic and chronic migraine. Cephalalgia. 2013;33:885-90.
23. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428-32.
24. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52:8-14.
25. • Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, et al. The cost-effectiveness of onabotulinumtoxin A for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013;16:877-87. This study focused on the prophylactic use of onabotulinumtoxin A is the first cost-effectiveness analysis for chronic migraine.
26. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921-36.
27. Mueller O, Diener HC, Dammann P, Rabe K, Hagel V, Sure U, et al. Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications. Cephalalgia. 2013. doi:10.1177/0333102413493193.